| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T390 |
0-29 |
Sentence |
denotes |
Lapatinib (Tykerb and Tyverb) |
| T391 |
30-98 |
Sentence |
denotes |
(GlaxcoSmithKline) Incomplete/variable absorption after oral dosing; |
| T392 |
99-251 |
Sentence |
denotes |
average absolute bioavailability 25% or less; consistent with low absorption/solubility, peak plasma concentrations do not occur until 4 h after dosing; |
| T393 |
252-299 |
Sentence |
denotes |
following 25 mg oral dose, the median Tmax=3 h; |
| T394 |
300-331 |
Sentence |
denotes |
geometric mean (95% CI) values; |
| T395 |
332-347 |
Sentence |
denotes |
Cmax=349 ng/mL; |
| T396 |
348-378 |
Sentence |
denotes |
AUC (0-infinity)=4410 ng*h/mL; |
| T397 |
379-396 |
Sentence |
denotes |
half-life 14.8 h; |
| T398 |
397-805 |
Sentence |
denotes |
absorption limited by first-pass metabolism by CYP3A4/5 and low solubility; transporters possibly involved, although lapatinib not a P-gp substrate (ABCB1) (219) Metabolized mainly by CYP3A4 and CYP3A5 and to a lesser extent by CYP2C19 and CYP2C8 1,250 mg orally once daily continuously in combination with capecitabine (for metastatic breast cancer); 1,500 mg orally once daily in combination with letrozole |
| T399 |
806-877 |
Sentence |
denotes |
(for hormone receptor positive HER2 positive metastatic breast cancer); |
| T400 |
878-1063 |
Sentence |
denotes |
>99% binding (AAG, HSA) Unlike gefitinib and erlotinib, pulmonary toxicity due to lapatinib is very rare; only one case of interstitial pneumonitis has been reported for lapatinib (220) |
